Classer les publications sur l'année
-
Biométrie et Analyses de bases de données
An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017
VERMERSCH P, SUCHET L, COLAMOARINO R, LAURENDEAU C, DETOURNAY B
Mult Scler Relat Disord ; 2020;46:102521
-
Économie de la santé
Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims.
DETOURNAY B, DEBOUVERIE M, PEREIRA O, SEYER D, SOUDAN M, COUROUVE L, JHOMA K, EPSTEIN J, GUILLEMIN F.
Mult Scler Relat Disord ; 2019;36:101396
-
Biométrie et Analyses de bases de données
Migraine burden and costs in france: a nationwide claims database analysis of triptan users.
DONNET A, EMERY C, ALY S, ALLAF B, CAYRE F, MAHIEU N, GOURMELEN J, LEVY P, FAGNANI F.
J Med Econ ; 2019;22(7):616-624
-
Économie de la santé
Multiple Source of Information to Characterize the Clinical, Therapeutic Management and Economic Burden of Patients with Multiple Sclerosis in France.
EPSTEIN J, DETOURNAY B , GUILLEMIN F, DEBOUVERIE M, COUSIN M, TEHARD B, GAROT T, BITOUN L, SOUDANT M , DEPOORTERE PH, PAU D
Value in Health ; 2017;20(9):a719
-
Économie de la santé
Effect of Multiple Sclerosis on Work Productivity
DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D
Value in Health ; 2017;20(9):a725
-
Économie de la santé
Effect of Multiple Sclerosis on Work Productivity
DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D
Value in Health ; 2017;20(9):a725
-
Économie de la santé
The Direct Cost of Patients With Multiple Sclerosis In France
DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B
Value in Health ; 2017;20(9):a721
-
Économie de la santé
The Direct Cost of Patients With Multiple Sclerosis In France
DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B
Value in Health ; 2017;20(9):a721
-
Pharmaco-Epidémiologie
Mortalité des sujets épileptiques vivant en institution spécialisée en France
JALLON P, DE ZELICOURT M, CACHERA C, FAGNANI F, LAURENDEAU C
Epilepsies ; 2008;20(3):179-187
-
Pharmaco-Epidémiologie
La mortalité observée à trois ans dans l’enquête CAROLE
JALLON P, DE ZELICOURT M, FAGNANI F, LAURENDEAU C, FAILLIOT M
Epilepsies ; 2007;19(3):173-177
-
Pharmaco-Epidémiologie
Prise en charge de la douleur en médecine générale : l’étude EPIDOL
EMERY C, GEORGE B, GOMAS JM, DELFIEU D, MIMAUD V, GUILLON P, FAGNANI F
Douleurs ; 6(6):366-373
-
Pharmaco-Epidémiologie
Epidemiology of restless legs syndrome in French adults A nationwide survey: The INSTANT Study
TISON F, CROCHARD A, LEGER D, BOUEE S, LAINEY E, EL HASNAOUI A
Neurology ; 65:239-246
-
Pharmaco-Epidémiologie
Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs : a prospective European study
PECHEVIS C, CLARKE E, VIEREGGE P, KHOSHNOOD B, DESCHASEAUX-VOINET C, BERDEAUX G, ZIEGLER M
Eur J Neurol ; 12:956-963
-
Pharmaco-Epidémiologie
Screening for Alzheimer’s disease with the short cognitive evaluation battery
ROBERT PH, SCHUCK S, DUBOIS B, OLIE JP, LEPINE JP, GALLARDA T, GONI S, TROY S
Dement Geriatr Cogn Disord ; 15:92-98
-
Économie de la santé
Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications
FAGNANI F, LAFUMA A, PECHEVIS M, RIGAUD AS, TRAYKOV L, SEUX ML, FORETTE F
Dement Geriatr Cogn Disord ; 17(1-2):5-13
